title: [Growth follow-up of SGA children after 3 years of GH treatment].
abstract: Eighty-five percent of children born with IUGR have spontaneous catch-up growth in the first 2 years of life; however, about 10 to 15% do not catch up. Numerous therapeutic trials have demonstrated the efficacy of GH treatment in these children. However, the duration of this treatment is still discussed.
  
  
  OBJECTIVE
  The aim of this study was to describe the evolution of growth during and after the end of treatment.
  
  
  METHODS
  This study followed 33 children in our unit, treated with growth hormone under the French indication (3 years of treatment followed by 1 year off treatment) and with a mean follow-up of 3 years after cessation.
  
  
  RESULTS
  During the 3 years of therapy, we confirmed an increase in growth velocity that resulted in a mean height above -2 standard deviation score (SDS) in 25 children at 3 years (mean height of 1.4 SDS). Among the 25 children who achieved a height above -2 SDS at three years and therefore stopped treatment, 15 resumed GH due to a secondary catch-down. Among children who didn't catch-up at 3 years, the continuation of GH treatment didn't seem to improve the growth.
authors.affiliation: Unité d'endocrinologie pédiatrique, maladies osseuses, génétique et gynécologie médicale, hôpital des Enfants, CHU de Toulouse, 330 avenue de Grande-Bretagne, Toulouse, France.
authors.forename: T
authors.initials: T
authors.lastname: Edouard
authors.forename: I
authors.initials: I
authors.lastname: Oliver
authors.forename: B
authors.initials: B
authors.lastname: Jouret
authors.forename: N
authors.initials: N
authors.lastname: Lounis
authors.forename: P
authors.initials: P
authors.lastname: Moulin
authors.forename: C
authors.initials: C
authors.lastname: Pienkowski
authors.forename: M
authors.initials: M
authors.lastname: Elefterion
authors.forename: J-P
authors.initials: JP
authors.lastname: Salles
authors.forename: M
authors.initials: M
authors.lastname: Tauber
mesh_terms: D000367:Age Factors; D001827:Body Height / Q000187:drug effects*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age / Q000254:growth & development*; D008297:Male; D012737:Sex Factors; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D019382:Human Growth Hormone